Serum Flt3L, sIL-2R, and Gas6 are associated with infection in indolent B-cell lymphoma
Infection poses a significant clinical challenge for patients with indolent B-cell lymphoma (iBCL), yet its assessment in this immunocompromised population remains difficult. We investigated the associations of serum FMS-like tyrosine kinase 3 ligand (Flt3L), soluble interleukin-2 receptor (sIL-2R), and growth arrest-specific 6 (Gas6) with infection status. Our goal was to evaluate their individual and combined discriminatory performance in iBCL. This retrospective, single-center cohort study included 95 iBCL patients with infection, 152 iBCL patients without infection, and 70 age- and sex-matched healthy controls. Serum Flt3L, sIL-2R, and Gas6 were quantified using enzyme-linked immunosorbent assay (ELISA), while procalcitonin (PCT) was measured via chemiluminescent immunoassay. We used multivariable logistic regression to examine independent associations with infection and assessed discrimination using the area under the receiver operating characteristic curve (AUC). Correlations with PCT were evaluated using Spearman rank correlation. Infections were predominantly community-acquired (71.6%), respiratory (50.5%), and bacterial (63.2%). Infection status was independently associated with age ≥65 years, Ann Arbor stage III-IV, chemotherapy within the preceding 3 months, hypogammaglobulinemia, diabetes mellitus, and elevated Flt3L, sIL-2R, and Gas6 levels. The combined three-biomarker model demonstrated superior apparent discrimination compared to individual biomarkers (AUC 0.89, 95% confidence interval 0.85-0.94, vs 0.73-0.76), achieving 80.0% sensitivity and 84.9% specificity. Among infected patients, all three biomarkers positively correlated with PCT (r = 0.44-0.51; all p < 0.001). Our findings indicate that higher Flt3L, sIL-2R, and Gas6 levels are associated with infection status in this pooled iBCL cohort. However, the three-marker model requires independent validation in homogeneous, subtype- and treatment-specific cohorts before clinical implementation.
Authors
- Pin Wu (ORCID: https://orcid.org/0000-0003-2176-1194)
- Mengxing Chen
Institutions
- Jiangnan University (CN)
- Wuxi No.2 People's Hospital (CN)
- Wuxi People's Hospital (CN)
Publication Details
- Journal
- Biomolecules and Biomedicine
- Published
- 2026-11-16
- DOI
- https://doi.org/10.17305/bb.2026.14831
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00